2016
DOI: 10.1016/j.breast.2016.02.014
|View full text |Cite
|
Sign up to set email alerts
|

Ductal carcinoma in situ diagnosed by breast needle biopsy: Predictors of invasion in the excision specimen

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
22
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 31 publications
(24 citation statements)
references
References 40 publications
2
22
0
Order By: Relevance
“…19 Data are considered to be unreliable when KA is <0.667. With 0.800 > KA ≥ 0.667, it is (2), non-solid ductal carcinoma in situ (DCIS) growth pattern versus solid DCIS growth pattern (3), presence or absence of intraductal calcifications (4), no necrosis versus any necrosis (5), no or single-cell necrosis versus focal or extensive necrosis (6), non-extensive necrosis versus extensive necrosis (7), absence or presence of apocrine differentiation (8), <1% periductal myxoid stroma versus ≥1% periductal myxoid stroma (9), <33% periductal myxoid stroma versus ≥33% periductal myxoid stroma (10), <66% periductal myxoid stroma versus ≥66% periductal myxoid stroma (11), no stromal inflammation versus any stromal inflammation (12), no or mild stromal inflammation versus moderate or extensive stromal inflammation (13), and non-extensive stromal inflammation versus extensive stromal inflammation (14). [Colour figure can be viewed at wileyonlinelibrary.com] advised to draw only tentative conclusions.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…19 Data are considered to be unreliable when KA is <0.667. With 0.800 > KA ≥ 0.667, it is (2), non-solid ductal carcinoma in situ (DCIS) growth pattern versus solid DCIS growth pattern (3), presence or absence of intraductal calcifications (4), no necrosis versus any necrosis (5), no or single-cell necrosis versus focal or extensive necrosis (6), non-extensive necrosis versus extensive necrosis (7), absence or presence of apocrine differentiation (8), <1% periductal myxoid stroma versus ≥1% periductal myxoid stroma (9), <33% periductal myxoid stroma versus ≥33% periductal myxoid stroma (10), <66% periductal myxoid stroma versus ≥66% periductal myxoid stroma (11), no stromal inflammation versus any stromal inflammation (12), no or mild stromal inflammation versus moderate or extensive stromal inflammation (13), and non-extensive stromal inflammation versus extensive stromal inflammation (14). [Colour figure can be viewed at wileyonlinelibrary.com] advised to draw only tentative conclusions.…”
Section: Discussionmentioning
confidence: 99%
“…The presence and degree of a chronic inflammatory infiltrate in the periductal stroma were recorded semiquantitatively as previously described . Four categories were discerned.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…This could be due to the fact that HER2‐positive invasive carcinomas have an extensive HER2‐positive in situ component, which is a risk factor for sampling error. However, further investigations are necessary as this upstage risk was not confirmed by others . Of note, increased stromal inflammation is strongly correlated with HER2‐positivity in pure DCIS, and stromal inflammation is more frequently observed in DCIS admixed with invasive carcinoma than in pure DCIS .…”
Section: Introductionmentioning
confidence: 86%
“…In addition, aside from the LARRIKIN trial, lesion size was not taken into account as an eligibility criterion. Lesion size has been known to be a predictive factor for invasion . Furthermore, a larger lesion size may also hint at the possibility that the low‐grade lesion might be associated with intermediate‐ or high‐grade foci.…”
Section: Current Trials Of Low‐risk Dcismentioning
confidence: 99%